Problems of Radiation Medicine and Radiobiology

Zh. M. Minchenko¹, T. F. Liubarets¹, V. V. Balan¹, O. O. Dmytrenko¹, T. Yu. Shlyakhtichenko¹,
V. O. Moyseyenko^2,3, Yu. O. Silayev¹, V. G. Bebeshko¹

¹State Institution «National Research Center for Radiation Medicine of the National Academy of Medical
  Sciences of Ukraine», 53 Yuriia Illienka St., Kyiv, 04050, Ukraine
²Bogomolets National Medical University of the Ministry of Health of Ukraine, 13 Tarasa Shevchenka
  Blvd., Kyiv, 01601, Ukraine
³Private Higher Educational Institution «International Academy of Ecology and Medicine»,
  121 Kharkivske Hwy., Kyiv, 02000, Ukraine

EFFICIENCY OF BONE MARROW PRECURSOR CELL COLONY-FORMING AS A PREDICTOR OF DISEASE COURSE IN PLASMA CELL MYELOMA PATIENTS WITH A HISTORY OF RADIATION EXPOSURE

Objective. Assessment of role of the bone marrow colony-forming efficiency in plasma cell myeloma patients at different stages of treatment as a prognostic criterion for the disease course. Materials and methods. The colony forming efficiency (CFE) was assayed in stage I–II plasma cell myeloma (PCM) patients (n = 37) aged 42–73, namely in patients survived after the Chornobyl NPP accident (n = 21) and persons not exposed to ionizing radiation (n = 16). There were 11 males exposed to ionizing radiation and having got stage I PCM, 9 males and 3 females exposed and having got stage II PCM, 3 males and 3 females not exposed and having got stage I PCM, 6 males and 2 females not exposed and having got stage II PCM. Healthy persons (n = 20) were included in the control group. Results. Number of the bone marrow (BM) granulocyte-macrophage colony-forming units (CFU-GM) in both exposed and not exposed PCM patients depended on a disease stage. CFU-GM was (16.7 ± 1.2) in the stage I PCM patients vs. (11.1 ± 1.1) in the stage II PCM ones both being lower (p < 0.05) compared to control (64.5 ± 2.2). Changes in cluster formation were similar, i.e. (37.7 ± 1.6) and (19.4 ± 1.3) correspondingly in the stage I and stage II PCM patients. Respective values in control were (89.8 ± 3.6). The CFE in stage I and stage II PCM patients at the time of diagnosis was lower (5.7 ± 1.5 and 2.4 ± 1.1 respectively) vs. control (39.5 ± 1.51, p < 0.05), but has increased in remission up to (29. 6 ± 1.8) and (13.8 ± 1.2) respectively. There was no difference at that between the irradiated and non-irradiated patients. Number of the fibroblast colony-forming units (CFU-F) in the stage I and stage II PCM patients during diagnosis, namely (43.9 ± 5.4) and (22.5 ± 3.7), was lower (p < 0.05) vs. control (110.5 ± 4.9). Upon reaching remission the CFU-F value increased significantly (p < 0.05), reaching (87.4 ± 4.2) and (55.6 ± 2.7) correspondingly in the stage I and stage II PCM patients. Conclusion. Dependence of the BM cell CFE on the stage of PCM and presence or absence of remission was established. Prognostic value of the CFE of BM CFU-GM in terms of life span of patients was shown (Ro Spearm = 0.39, p < 0.02), namely in case of CFE > 20 before the polychemotherapy administration the life span of PCM patients was significantly longer vs. cases of CFE < 20.
Key words: plasma cell myeloma, bone marrow, granulocyte-macrophage colony-forming unit, fibroblast colony-forming unit, cluster.

Problems of Radiation Medicine and Radiobiology.
2020;25:490-501. doi: 10.33145/2304-8336-2020-25-490-501

full text

1. Tian F, Li J, Li Y, Luo S. Enhancement of myeloma development mediated though myeloma cell-Th2 cell interactions after microbial antigen presentation by myeloma cells and DCs. Blood Cancer J. 2012;2(6):e74. doi:10.1038/bcj.2012.19.
2. Tian F, Lu B, Chen Z, Liu J, Ji D, Li J, et al. Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2-myeloma cell interaction. BMC Cancer. 2019;19(1):1246. doi: 10.1186/s12885-019-6469-4.
3. Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, et al. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer. 2015;15:864. doi: 10.1186/s12885-015-1892-7.
4. Reagan MR, Mishima Y, Glavey SV, Zhang Y, Manier S, Lu ZN, et al. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood. 2014;124(22):3250-9. doi: 10.1182/blood-2014-02-558007.
5. Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, et al. Characterization of multiple myeloma vesicles by label-free relative quantitation. Proteomics. 2013;13(20):3013-3029. doi: 10.1002/pmic.201300142.
6. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004;64(6):2016-2023. doi: 10.1158/0008-5472.can-03-1131.
7. Alameda D, Saez B, Lara-Astiaso D, Sarvide S, Lasa M, Alignani D, et al. Characterization of freshly isolated mesenchymal stromal cells from healthy and multiple myeloma bone marrow: transcriptional modulation of the microenvironment. Haematologica. 2020:haematol.2019.235135. doi: 10.3324/haematol.2019.235135.
8. Groen RW, Noort WA, Raymakers RA, Prins HJ, Aalders L, Hofhuis FM, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood. 2012 Jul 19;120(3):e9-e16. doi: 10.1182/blood-2012-03-414920.
9. Kriangkum J, Motz SN, Debes Marun CS, Lafarge ST, Gibson SB, Venner CP, Johnston JB, Belch AR, Pilarski LM. Frequent occurrence of highly expanded but unrelated B-cell clones in patients with multiple myeloma. PLoS One. 2013;8(5):e64927. doi: 10.1371/journal.pone.0064927.
10. Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest. 2015;125(7):2904. doi: 10.1172/JCI82646.
11. Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, Oyajobi BO, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015;29(10):2110-2113. doi: 10.1038/leu.2015.79.
12. Millar BC, Bell JB, Lakhani A, Ayliffe MJ, Selby PJ, McElwain TJ. A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro. Br J Haematol. 1988;69(2):197-203. doi: 10.1111/j.1365-2141.1988.tb07622.x.
13. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004 Mar 15;103(6):2332-2336. doi: 10.1182/blood-2003-09-3064.
14. Desantis V, Frassanito MA, Tamma R, Saltarella I, Di Marzo L, Lamanuzzi A, et al. Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma. Ann Hematol. 2018 Jul;97(7):1251-1258. doi: 10.1007/s00277-018-3293-x.
15. Hosen N. Multiple myeloma-initiating cells. Int J Hematol. 2013;97(3):306-312. doi: 10.1007/s12185-013-1293-0.
16. Solimando AG, Da Via MC, Cicco S, Leone P, Di Lernia G, Giannico D, et al. High-risk multiple myeloma: integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment. J Clin Med. 2019 Jul 9;8(7):997. doi: 10.3390/jcm8070997.